39,413 Shares in Omnicell, Inc. (NASDAQ:OMCL) Bought by Seven Eight Capital LP

Seven Eight Capital LP purchased a new position in Omnicell, Inc. (NASDAQ:OMCL) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 39,413 shares of the company’s stock, valued at approximately $1,483,000. Seven Eight Capital LP owned 0.09% of Omnicell as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OMCL. Pacer Advisors Inc. lifted its stake in Omnicell by 321,488.8% in the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock worth $39,814,000 after acquiring an additional 1,057,698 shares during the period. Vanguard Group Inc. lifted its stake in Omnicell by 15.1% in the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock worth $231,374,000 after acquiring an additional 674,824 shares during the period. Norges Bank purchased a new stake in Omnicell in the fourth quarter worth $18,802,000. Jacobs Levy Equity Management Inc. lifted its stake in Omnicell by 12,425.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 482,488 shares of the company’s stock worth $21,731,000 after acquiring an additional 478,636 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in Omnicell in the fourth quarter worth $13,687,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Down 0.7 %

Omnicell stock traded down $0.22 on Friday, hitting $29.72. 302,325 shares of the stock traded hands, compared to its average volume of 380,294. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. The firm has a market cap of $1.36 billion, a P/E ratio of -64.61, a price-to-earnings-growth ratio of 105.39 and a beta of 0.84. The business’s fifty day simple moving average is $29.39 and its 200 day simple moving average is $31.21. Omnicell, Inc. has a 1 year low of $25.69 and a 1 year high of $75.35.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The firm had revenue of $246.15 million during the quarter, compared to the consensus estimate of $235.70 million. As a group, sell-side analysts forecast that Omnicell, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Benchmark reissued a “buy” rating and set a $38.00 price objective on shares of Omnicell in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and an average price target of $42.20.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.